Patents by Inventor Christopher M. Clemens
Christopher M. Clemens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160282353Abstract: Provided is an assay system and method that includes binding a conjugate to a target receptor on a surface of malignant blood cells included in the liquid medium to form labeled malignant blood cells. The liquid medium including the labeled malignant blood cells is exposed to a magnetic field to separate the labeled malignant blood cells from unlabeled blood cells in the liquid medium. In the presence of the magnet field, at least a portion of the liquid medium is removed to isolate the labeled malignant blood cells separated by the magnetic field. A sample comprising at least a portion of the labeled malignant blood cells separated by the magnetic field is then introduced into a flow cytometer to quantify the labeled malignant blood cells present in the sample.Type: ApplicationFiled: March 28, 2016Publication date: September 29, 2016Inventors: Christopher M. Clemens, Joseph R. Firca
-
Publication number: 20040062771Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.Type: ApplicationFiled: September 15, 2003Publication date: April 1, 2004Applicant: PROMEGA CorporationInventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
-
Patent number: 6693083Abstract: A composition for intracellular delivery of a chemical agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chemical agent and at least one copy of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a water soluble polymer. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the composition. The composition also preferably includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is a polyalkylene oxide, such as polyethlene glycol and polyethylene oxide, and activated derivatives thereof. The composition can further comprise a carrier such as another water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.Type: GrantFiled: February 12, 2001Date of Patent: February 17, 2004Assignee: Watson Pharmaceuticals, Inc.Inventors: Ramesh K. Prakash, Christopher M. Clemens
-
Patent number: 6656468Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.Type: GrantFiled: March 5, 1997Date of Patent: December 2, 2003Assignee: Promega CorporationInventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
-
Publication number: 20030012785Abstract: A composition for intracellular delivery of a chemical agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chemical agent and at least one copy of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a water soluble polymer. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the composition. The composition also preferably includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is a polyalkylene oxide, such as polyethlene glycol and polyethylene oxide, and activated derivatives thereof. The composition can further comprise a carrier such as another water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.Type: ApplicationFiled: February 12, 2001Publication date: January 16, 2003Inventors: Ramesh K. Prakash, Christopher M. Clemens
-
Patent number: 6251866Abstract: A composition for intracellular delivery of a chemical agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chemical agent and at least one copy of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a water soluble polymer. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the composition. The composition also preferably includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is a polyalkylene oxide, such as polyethlene glycol and polyethylene oxide, and activated derivatives thereof. The composition can further comprise a carrier such as another water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.Type: GrantFiled: August 4, 1998Date of Patent: June 26, 2001Assignee: Watson Laboratories, Inc.Inventors: Ramesh K. Prakash, Christopher M. Clemens
-
Patent number: 5814477Abstract: The present invention includes methods for the production and purification of recombinant clostridial toxin proteins.Type: GrantFiled: June 1, 1995Date of Patent: September 29, 1998Assignee: Ophidian Pharmaceuticals, Inc.Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
-
Patent number: 5762934Abstract: The present invention includes methods and compositions for treating humans and other animals intoxicated with at least one clostridial toxin by administration of antitoxin. In particular, the antitoxin directed against these toxins is produced in avian species. This avian antitoxin is designed so as to be orally administerable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution).Type: GrantFiled: June 1, 1995Date of Patent: June 9, 1998Assignee: Ophidian Pharmaceuticals, Inc.Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
-
Patent number: 5719267Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.Type: GrantFiled: June 1, 1995Date of Patent: February 17, 1998Assignee: Ophidian Pharmaceuticals Inc.Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
-
Patent number: 5601823Abstract: The present invention includes methods and compositions for treating humans and other animals intoxicated with at least one Clostridial toxin by administration of antitoxin. In particular, the antitoxin directed against these toxins is produced in avian species. This avian antitoxin is designed so as to be orally administerable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution).Type: GrantFiled: December 2, 1993Date of Patent: February 11, 1997Assignee: Ophidian Pharmaceuticals, Inc.Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
-
Patent number: 5599539Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.Type: GrantFiled: June 7, 1994Date of Patent: February 4, 1997Assignee: Ophidian Pharmaceuticals, Inc.Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens